Sanofi Stays Mum On Genzyme But Near-Term M&A Appears Likely
Sanofi-Aventis is dangling over a dangerous patent cliff, facing generic competition to Lovenox, Plavix and other top-selling drugs, and the company's solution to scramble back to safer ground could be a significant acquisition
You may also be interested in...
French pharma's initial offer in the $67 to $70 per share range expected to rise, perhaps into the $80s.
Company claims the agency approved the generic although the innovator drug had not been fully characterized, but odds are against a Sanofi win in court.
Sandoz has a monopoly on the generic enoxaparin market for now, but Teva insists its ANDA is progressing at FDA.